Collegium Pharmaceutical grabs $50 mln

Canton, Massachusetts-based Collegium Pharmaceutical Inc, a specialty pharmaceutical company focused on treating chronic pain, has secured $50 million in funding. TPG Biotech led the round with participation from RA Capital Management, Adage Capital Management, Rock Springs Capital, EcoR1 Capital, Eventide Asset Management, Aperture Venture Partners, Longitude Capital, Skyline Ventures, Frazier Healthcare and Boston Millennia Partners. In conjunction with this financing, Dr. Eran Nadav, a partner and managing director at TPG Biotech, has been added to Collegium's board of directors.

North AmericaUSBriefs